Analyst: Payer hurdles hit dispense rates on Sanofi and Regeneron's eczema blockbuster-to-be Dupixent
admin 14th July 2017 Uncategorised 0The road to blockbuster land is steeper and rougher than it used to be, and payer footprints are all over it. Consider the much-anticipated Dupixent. Even with early coverage secured with upfront negotiations, obstacles are hampering its path to patients’ hands, an analyst’s detective work found.
More: Analyst: Payer hurdles hit dispense rates on Sanofi and Regeneron's eczema blockbuster-to-be Dupixent
Source: fierce